Skip Nav Destination
Issues
November 2019
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
ISSN 2235-1795
EISSN 1664-5553
In this Issue
Liver Cancer 2019, Vol. 8, No. 6
Editorial
Review
Systemic Treatment Options in Hepatocellular Carcinoma
Liver Cancer (2019) 8 (6): 427–446.
https://doi.org/10.1159/000499765
Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma
Takashi Kokudo; Kiyoshi Hasegawa; Chikara Shirata; Meguri Tanimoto; Takeaki Ishizawa; Junichi Kaneko; Nobuhisa Akamatsu; Junichi Arita; Nicolas Demartines; Emilie Uldry; Norihiro Kokudo; Nermin Halkic
Liver Cancer (2019) 8 (6): 447–456.
https://doi.org/10.1159/000501368
Original Paper
Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
Jean-Luc Raoul; Xavier Adhoute; Guillaume Penaranda; Hervé Perrier; Paul Castellani; Valérie Oules; Marc Bourlière
Liver Cancer (2019) 8 (6): 457–467.
https://doi.org/10.1159/000497161
Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma
Liver Cancer (2019) 8 (6): 468–479.
https://doi.org/10.1159/000500461
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Li-Chun Lu; Chiun Hsu; Yu-Yun Shao; Yee Chao; Chia-Jui Yen; I-Lun Shih; Yi-Ping Hung; Chun-Jung Chang; Ying-Chun Shen; Jhe-Cyuan Guo; Tsung-Hao Liu; Chih-Hung Hsu; Ann-Lii Cheng
Liver Cancer (2019) 8 (6): 480–490.
https://doi.org/10.1159/000501275
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization
Clemens Schotten; Lars P. Bechmann; Paul Manka; Jens Theysohn; Alexander Dechêne; Amr El Fouly; Francesco Barbato; Ursula Neumann; Sonia Radünz; Svenja Sydor; Dominik Heider; Marino Venerito; Ali Canbay; Guido Gerken; Ken Herrmann; Heiner Wedemeyer; Jan Best
Liver Cancer (2019) 8 (6): 491–504.
https://doi.org/10.1159/000501484
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Masatoshi Kudo; Kazuomi Ueshima; Yasutaka Chiba; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Yasuaki Arai
Liver Cancer (2019) 8 (6): 505–519.
https://doi.org/10.1159/000503032
Letter to the Editor
Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma
Liver Cancer (2019) 8 (6): 520–521.
https://doi.org/10.1159/000496546
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand
Liver Cancer (2019) 8 (6): 524–526.
https://doi.org/10.1159/000501485